Literature DB >> 11451823

Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis.

A Baydur1, M Alsalek, S G Louie, O P Sharma.   

Abstract

BACKGROUND: Sarcoidosis is a systemic granulomatous disorder that is estimated to involve the skeletal muscles in up to 50% of patients. There is little information on the relationship among respiratory muscle strength, lung volumes, and the degree of dyspnea in patients with sarcoidosis. DESIGN AND PATIENTS: Lung function and maximal respiratory muscle force generation were measured in 36 patients with sarcoidosis (24 patients with pulmonary parenchymal infiltration) and 25 control subjects free of cardiorespiratory disease. Dyspnea in the sarcoidosis patients was quantitated by a score based on an activity tolerance assessment scale (ranging from rest to climbing hills or stairs).
SETTING: Outpatient clinics of two teaching hospitals.
RESULTS: Mean FVC, maximal voluntary ventilation, total lung capacity (TLC), functional residual capacity, residual volume (RV), and diffusing capacity of the lung for carbon monoxide (DLCO) were all at least 16% less than corresponding control values (in all cases, p < 0.001), while maximal inspiratory mouth pressure (PImax) and maximal expiratory mouth pressure (PEmax) were 37% and 39% less, respectively, than control values (both at p < 0.0001). PImax and PEmax declined with increasing dyspnea in a more graded, steady manner than did spirometric and DLCO values. For all measurements, however, the lowest mean values were found in patients with the most severe level of dyspnea. Strong inverse relationships were observed between PEmax and PImax with dyspnea level (p < 0.0001 and p < 0.01, respectively). Both PImax and PEmax correlated best with absolute values of FVC, while only PEmax correlated with RV (absolute and percent predicted) and percent predicted values of TLC.
CONCLUSIONS: Maximal respiratory pressures correlate more closely with dyspnea level than lung volumes and DLCO. Since dyspnea is the most common presentation in early to moderately advanced sarcoidosis, respiratory pressures may be a more reliable index of functional work capacity and reflection of activities of daily living than standard tests of lung function.

Entities:  

Mesh:

Year:  2001        PMID: 11451823     DOI: 10.1378/chest.120.1.102

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  20 in total

Review 1.  Respiratory and lower limb muscle function in interstitial lung disease.

Authors:  Marios Panagiotou; Vlasis Polychronopoulos; Charlie Strange
Journal:  Chron Respir Dis       Date:  2016-01-14       Impact factor: 2.444

Review 2.  Patient reported outcome measures (PROMs) in sarcoidosis.

Authors:  Rikke Flor Thunold; Anders Løkke; Adam Langballe Cohen; Hilberg Ole; Elisabeth Bendstrup
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

3.  The indications for the treatment of sarcoidosis: Wells Law.

Authors:  Robert P Baughman; Marc A Judson; Athol Wells
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 4.  The Clinical Features of Sarcoidosis: A Comprehensive Review.

Authors:  Marc A Judson
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

5.  Ventilatory disturbances in patients with intrathoracic sarcoidosis - a study from a functional and histological perspective.

Authors:  Diana Calaras; Oxana Munteanu; Valentina Scaletchi; I Simionica; V Botnaru
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

6.  Relationship between radiologic patterns, pulmonary function values and bronchoalveolar lavage fluid cells in newly diagnosed sarcoidosis.

Authors:  Regina Aleksonienė; Ingrida Zeleckienė; Mindaugas Matačiūnas; Roma Puronaitė; Laimutė Jurgauskienė; Radvilė Malickaitė; Edita Strumilienė; Vygantas Gruslys; Rolandas Zablockis; Edvardas Danila
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

7.  Exercise capacity, muscle strength, and fatigue in sarcoidosis: a follow-up study.

Authors:  Rik G J Marcellis; Antoine F Lenssen; Stephan Kleynen; Jolanda De Vries; Marjolein Drent
Journal:  Lung       Date:  2013-04-05       Impact factor: 2.584

8.  Reduction of exercise capacity in sarcoidosis in relation to disease severity.

Authors:  Anastasios Kallianos; Paul Zarogoulidis; Fotini Ampatzoglou; Georgia Trakada; Elias Gialafos; Georgia Pitsiou; Athanasia Pataka; Lemonia Veletza; Konstantinos Zarogoulidis; Wolfgang Hohenforst-Schmidt; Dimitris Petridis; Ioannis Kioumis; Aggeliki Rapti
Journal:  Patient Prefer Adherence       Date:  2015-08-18       Impact factor: 2.711

9.  Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety.

Authors:  Sasan Tavana; Hassan Argani; Sharareh Gholamin; Seyed-Mostafa Razavi; Marzieh Keshtkar-Jahromi; Amir S Talebian; Keivan G Moghaddam; Zahra Sepehri; Talat M Azad; Maryam Keshtkar-Jahromi
Journal:  Influenza Other Respir Viruses       Date:  2011-09-28       Impact factor: 4.380

10.  Qualitative aspects of exertional dyspnea in patients with restrictive lung disease.

Authors:  Pierantonio Laveneziana
Journal:  Multidiscip Respir Med       Date:  2010-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.